Molecular subtypes and genetic alterations may determine response to lung cancer therapyMay 14, 2012
A UNC-led team of scientists has shown for the first time that lung cancer molecular subtypes correlate with distinct genetic alterations and with patient response to therapy. These findings in pre-clinical models and patient tumor samples build on their previous report of three molecular subtypes of non-small cell lung cancer and refines their molecular analysis of tumors.
Their findings were published in the May 10, 2012 online edition of the Public Library of Science One.
Study senior author, Neil Hayes, MD, MPH, associate professor of medicine, says, "It has been known for about a decade of using gene expression arrays that "molecular subtypes" exist. These subtypes have molecular "fingerprints" and frequently have different clinical outcomes. However, the underlying etiologies of the subtypes have not been recognized. Why do tumors form subtypes?
"Our study shows that tumor subtypes have different underlying alterations of DNA as part of the difference. These differences are further evidence of the importance of subtypes and the way we will use them. For example, the mutations are different which may imply much more ability to target than previously recognized. Also, we are starting to get a suggestion that these subtypes may reflect different cells of origin that rely on different cancer pathways. This is further unlocking the diversity of this complex disease." Hayes is a member of UNC Lineberger Comprehensive Cancer Center.
The team first defined and reported in 2006 on three lung cancer molecular subtypes, named according to their genetic pattern - bronchoid, squamoid and magnoid.
In this PLoS One paper they sought to determine if distinct genetic mutations co-occur with each specific molecular subtypes. They found that specific genetic mutations were associated with each subtype and that these mutations may have independent predictive value for therapeutic response.
University of North Carolina School of Medicine
Related Molecular Subtypes Current Events and Molecular Subtypes News Articles
Complete resection of high-grade brain cancer yields better survival in children -- especially girls
For children with aggressive brain cancers called high-grade gliomas (HGG), the chances of survival are improved when surgery is successful in eliminating all visible cancer, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
New breast cancer screening analysis confirms biennial interval optimal for average risk women
Results from a second comprehensive analysis of mammography screening, this time using data from digital mammography, confirms findings from a 2009 analysis of film mammography: biennial (every two years) screening offers a favorable balance of benefits to harm for women ages 50 to 74 who have an average risk of developing breast cancer.
Whose numbers determine cost-effectiveness of targeted anti-cancer therapies?
Health economics helps insurers, health care systems and providers make treatment decisions based on the cost of extra "units" of health arising from a specific treatment.
Thyroid cancer genome analysis finds markers of aggressive tumors
A new comprehensive analysis of thyroid cancer from The Cancer Genome Atlas Research Network has identified markers of aggressive tumors, which could allow for better targeting of appropriate treatments to individual patients.
TCGA study improves understanding of genetic drivers of thyroid cancer
A comprehensive analysis of the genomes of nearly 500 papillary thyroid carcinomas (PTC) - the most common form of thyroid cancer - has provided new insights into the roles of frequently mutated cancer genes and other genomic alterations that drive disease development.
Researchers find why depression and aging linked to increased disease risk
Psychological stress and stress-related psychiatric disorders are associated with increased risk for aging-related diseases, but the molecular mechanisms underlying this relation are unknown.
Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.
EORTC Breast cancer trial shows pathological complete response is independent predictor of favorable clinical outcome
Results of EORTC trial 10994 appearing in the Annals of Oncology show that pathological complete response after neoadjuvant chemotherapy is an independent predictive factor of favorable clinical outcomes in all molecular subtypes of breast cancer.
VHIO genomic study identifies subgroups of HER2+ breast cancer with varying sensitivities
Research led by the Translational Genomics Group at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona has not only shown that HER2+ breast cancer can be classified into four different subtypes, but also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy.
Children's National Researcher Authors Study on Pediatric Brain Stem Tumors
Children's National researcher, Javad Nazarian, PhD, authored a new study entitled, "Comparative Multidimensional Molecular Analyses of Pediatric Diffuse Intrinsic Pontine Glioma Reveals Distinct Molecular Subtypes."
More Molecular Subtypes Current Events and Molecular Subtypes News Articles